



Intranasal Therapeutics, Inc.

Intranasal Therapeutics Names Jeffrey Edelson, MD, Executive Vice President, R&D and Chief Medical Officer

Saddle Brook, NJ, July 8, 2008 – Intranasal Therapeutics, Inc. (ITI), a specialty pharmaceutical company focused on developing nasally delivered, preservative-free drug products, today announced a key executive addition to the company's leadership team. Jeff Edelson, MD, previously employed by Johnson & Johnson (J&J) as Vice President, Internal Medicine and Therapeutic Area Head – Novel Therapeutics, has joined ITI as Executive Vice President, R&D, and Chief Medical Officer.

"We are delighted to have someone of Jeff's caliber as a member of the ITI management team," said Peter F. Young, President and Chief Executive Officer of ITI. "Jeff is a highly experienced product development and clinical research executive with an impressive track record of accomplishment. He will add enormously to ITI's strategic reach and product development capability."

Dr. Edelson brings over 20 years of clinical research and development experience to ITI. His prior industry experience includes leadership roles of progressive responsibility in areas of pulmonary and critical care medicine, oncology, hematology, supportive care and immunology for Johnson and Johnson, Aventis, Therion Biologics, SmithKline Beecham /GlaxoSmithkline. Dr. Edelson is also a seasoned technical product analyst and leader of multifunctional and alliance teams.

Prior to joining the pharmaceutical industry, Dr. Edelson was the founding Director of Research and Academic Affairs at the Health Sciences Research Centre at St. Michael's Hospital in Toronto, Canada and a clinician / scientist and Assistant Professor of Medicine at the University of Toronto. His research endeavors spanned basic cell biology, translational medicine, clinical investigation and health service research.

Dr. Edelson holds an MD degree and an MHSc (Master of Health Sciences Administration) from the University of Toronto, Canada, where he trained in internal medicine and respiratory and critical care medicine, and where he was awarded a Robert Wood Johnson fellowship in 1997. He continues to teach part time in the Pulmonary and Critical Care program of the University of Pennsylvania, where he holds the rank of Adjunct Associate Professor of Medicine.

Intranasal Therapeutics, Inc. Adds Key Executive to Management Team
Page 2 of 2

About ITI

Intranasal Therapeutics, Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative nasally delivered pharmaceutical products, with a particular focus on drugs to treat pain and central nervous system disorders for which there is proven, unsatisfied consumer need. The company currently has several significant products in its clinical development pipeline or in formulation and preclinical development. ITI's goal is to become a leader in the field of intranasal pharmaceuticals by applying formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. For more information, please visit the ITI web site at www.intranasal.com.

###

Contacts:

Peter Young
Chief Executive Officer
Intranasal Therapeutics, Inc.
Tel.: 201-843-3308

Joan Kureczka
Kureczka/Martin Associates
Tel: (415) 821-2413
Email: Jkureczka@comcast.net